Deepak Cyril D’Souza
Vikram Sodhi Professor of Psychiatry at Yale School of Medicine; Staff Psychiatrist at VA Connecticut Healthcare System
Data updated
Research Footprint
Deepak Cyril D’Souza appears in 11 tracked papers (2012–2025), most studied alongside Psilocybin, Salvia Divinorum and Ketamine, across Anxiety Disorders, Depressive Disorders and Headache Disorders (Cluster & Migraine).
Most-cited paper: Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder (150 citations).
Frequent co-authors: Brian Pittman, Emmanuelle Schindler and Christopher Gottschalk.
Background & Research
Deepak Cyril D’Souza, MD, is a Professor of Psychiatry at Yale School of Medicine and a staff psychiatrist at VA Connecticut Healthcare System. He directs the Schizophrenia Neuropharmacology Research Group at Yale and has extensive experience in psychopharmacology, neuropsychiatry, and early-phase clinical trials. His recent work includes studies of ketamine, psilocybin, and intravenous DMT for psychiatric conditions.
Key Impact
He is a leading Yale psychiatry researcher whose clinical trials helped establish human research on psychedelics such as psilocybin and DMT, alongside work on ketamine and other neuropsychiatric therapeutics.
Collaboration Network
12 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Deepak Cyril D’Souza is associated with.
Yale School of Medicine Center for Brain Mind Health
academicA research center within Yale School of Medicine focused on understanding the neuroscience of consciousness, mental health disorders, and the mechanisms of psychoactive substances. The Center for Brain and Mind Health bridges psychiatry and neuroscience to advance knowledge of brain-mind relationships and explore novel therapeutic approaches including psychedelic-assisted treatment at Yale.
View stakeholder →VA Connecticut Healthcare System
governmentThe VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.
View stakeholder →Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →